INBS

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

EFFECT - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

424B3 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

S-3 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

D - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET. The moderated discussion will feature Harry Simeonidis, President and CEO, and Peter Passaris, Vice President of Product Development. Topics will include the Company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, the supporting clinical data, the FDA review process, and the Company’s commercial progress outside the United States. Event Detail

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA), seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the "System") for detection of the opiate codeine. The submission represents the culmination of data from a structured, multi-study clinical program that the Company has executed throughout 2026, targeting entry into the multi-billion-dollar U.S. drug screening market. The Company’s 51

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the results of its latest Method Comparison Study for its Intelligent Fingerprinting Drug Screening System (the "System") to detect the opiate codeine. Conducted across three independent U.S. clinical sites, the study represents the most comprehensive evaluation of the System in the Company's FDA 510(k) clinical study program. The study results show substantially improved performance compared to the Company's prior Method Comparison Study, announced in November of 2024

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has entered into a securities purchase agreement with a single existing institutional investor to issue, in a private placement priced at-the-market under Nasdaq rules, 2,036,659 shares of common stock (or Series M pre-funded warrants in lieu thereof), Series N-1 warrants to purchase up to an aggregate of 2,036,659 shares of common stock, and Series N-2 warrants to purchase up to an aggregate of 2,036,659 shares of common stock, at a combined purchase price of

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

10-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year 502 active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries Company made substantial progress toward FDA clearance and planned market expansion during the year NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlig

NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its Intelligent Fingerprinting Drug Screening business has been recertified to the ISO 13485:2016 quality management system standard, the internationally recognized benchmark for medical device manufacturers. The recertification, issued by the British Standards Institution (BSI), is effective October 14, 2026, and will be valid for three years. On February 2, 2026, the U.S. FDA's amended Quality Management System Regulation (QMSR) came into effect, formally updati

SCHEDULE 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, one of several studies underpinning the Company's FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. All clinical data collection across the Company's FDA 510(k) clinical study program is now complete. Following ICH GCP (International Council for Harmonisation Good Clinical Practice) guidelines, the study was conducted a

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System, supporting its FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. The study was conducted in partnership with CenExel Clinical Research, Inc., following FDA guidance and ICH GCP (International Council for Harmonisation Good Clinical Practice) standards. The study was designed to evaluate how effectively operators could be trained to administ

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)